Gene-Editing Shot Cuts "Bad" Cholesterol 62% in Trial

Imagine lowering your cholesterol with a single shot instead of taking pills every day for the rest of your life. That future just took a major step closer to reality.

Eli Lilly announced Monday that its gene-editing therapy, VERVE-102, reduced LDL cholesterol levels by 62% in patients who received the highest dose during a Phase 1 clinical trial. LDL cholesterol, often called "bad" cholesterol, is a leading contributor to heart disease.

The treatment works by editing genes to permanently change how the body processes cholesterol. Unlike daily pills that many patients forget or stop taking, this therapy could offer lifelong protection with just one injection.

Heart disease kills more people worldwide than any other condition. Yet many patients struggle to stick with existing cholesterol medications over time, leaving them vulnerable to heart attacks and strokes.

Lilly acquired the therapy last year when it bought Verve Therapeutics for $1 billion. Company executives see it as a potential game changer for preventing heart disease on a massive scale.

The early trial also delivered another crucial win: no serious treatment-related side effects occurred. This marks important progress after Verve had to abandon its first candidate due to safety concerns.

The study tested only a small number of participants, as Phase 1 trials typically do. Larger studies will need to confirm these results and track patients over many years to ensure the therapy remains safe and effective.

The Bright Side

Gene editing for common diseases like high cholesterol was science fiction just a decade ago. Now it's showing real results in real people.

This isn't just about one company or one therapy. The success of VERVE-102 validates an entirely new approach to preventing disease by rewriting our genetic code in targeted, helpful ways.

If future studies confirm these early findings, millions of people could potentially avoid heart attacks and strokes without the daily burden of remembering pills. That's especially important for people who can't afford medications or lack consistent access to healthcare.

The technology could also pave the way for similar one-time treatments for other chronic conditions that require lifelong medication.

Larger trials are already in the works to test whether this early promise holds up in thousands of patients over many years.